Telomerase-specific oncolytic adenovirus: Antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells

Head and Neck

Volumn 36, Issue 3, 2014, Pages 411-418

  Takahashi, Hideaki ^a   Hyakusoku, Hiroshi ^a   Horii, Chihiro ^a   Takahashi, Masahiro ^a   Nishimura, Goshi ^a   Taguchi, Takahide ^a   Kondo, Norio ^b   Sakakibara, Atsuko ^a   Urata, Yasuo ^c   Sano, Daisuke ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^c National Institute of Infectious Diseases   (Japan)

Author keywords

head and neck squamous cell carcinoma; OBP 301; radiation sensitivity; telomerase; virotherapy

Indexed keywords

HEAD AND NECK SQUAMOUS CELL CARCINOMA; OBP-301; RADIATION SENSITIVITY; TELOMERASE; VIROTHERAPY;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; DNA REPAIR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC CELLS, CIRCULATING; ONCOLYTIC VIROTHERAPY; RADIATION, IONIZING; RADIOTHERAPY DOSAGE; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894237195     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23309     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bhide SA, Nutting CM,. Advances in radiotherapy for head and neck cancer. Oral Oncol 2010; 46: 439-441.
3. Goldberg HI, Lockwood SA, Wyatt SW, Crossett LS,. Trends and differentials in mortality from cancers of the oral cavity and pharynx in the United States, 1973-1987. Cancer 1994; 74: 565-572.
4. Cohen EE, Lingen MW, Vokes EE,. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22: 1743-1752.
5. de Lange T,. How telomeres solve the end-protection problem. Science 2009; 326: 948-952.
6. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
7. Kunická Z, Mucha I, Fajkus J,. Telomerase activity in head and neck cancer. Anticancer Res 2008; 28: 3125-3129.
8. Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998; 18: 65-68.
9. Liao Z, Huang C, Zhou F, et al. Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. Cancer Lett 2009; 283: 20-28.
10. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10 (1 Pt 1): 285-292.
11. Hashimoto Y, Watanabe Y, Shirakiya Y, et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 2008; 99: 385-390.
12. Li D, Duan L, Freimuth P, O'Malley BW Jr,. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999; 5: 4175-4181.
13. Kondo N, Tsukuda M, Kimura M, et al. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Oncol Rep 2010; 23: 355-363.
14. Sakakibara A, Tsukuda M, Kondo N, et al. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines. Auris Nasus Larynx 2011; 38: 589-599.
15. Kuroda S, Fujiwara T, Shirakawa Y, et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 2010; 70: 9339-9348.
16. Takakura M, Nakamura M, Kyo S, et al. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther 2010; 17: 11-19.
17. Liu D, Kojima T, Ouchi M, et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther 2009; 8: 980-987.
18. Fujita K, Kimura M, Kondo N, et al. Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma. Oncol Rep 2008; 20: 1363-1368.
19. Masters JR, Thomson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001; 98: 8012-8017.
20. Sano D, Matsumoto F, Valdecanas DR, et al. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 2011; 17: 1815-1827.
21. Buchholz TA, Wu X, Hussain A, et al. Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer 2002; 97: 557-561.
22. Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ,. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002; 8: 293-298.
23. Sano D, Myers JN,. Xenograft models of head and neck cancers. Head Neck Oncol 2009; 1: 32.
24. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999; 59: 107-114.
25. Petrini JH,. The mammalian Mre11-Rad50-nbs1 protein complex: integration of functions in the cellular DNA-damage response. Am J Hum Genet 1999; 64: 1264-1269.
26. Mirzoeva OK, Petrini JH,. DNA damage-dependent nuclear dynamics of the Mre11 complex. Mol Cell Biol 2001; 21: 281-288.
27. Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD,. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J 2003; 22: 6610-6620.
28. Boyer J, Rohleder K, Ketner G,. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 1999; 263: 307-312.
29. McCaul JA, Gordon KE, Minty F, Fleming J, Parkinson EK,. Telomere dysfunction is related to the intrinsic radio-resistance of human oral cancer cells. Oral Oncol 2008; 44: 261-269.
30. Latre L, Tusell L, Martin M, et al. Shortened telomeres join to DNA breaks interfering with their correct repair. Exp Cell Res 2003; 287: 282-288.
31. Hashimoto Y, Tazawa H, Teraishi F, et al. The hTERT Promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment. PLoS One 2012; 7: e39292.
32. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2561.
33. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012; 18: 290-300.
34. Sano D, Xie TX, Ow TJ, et al. Disruptive TP53 Mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res 2011; 17: 6658-6670.
35. Querido E, Marcellus RC, Lai A, et al. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J Virol 1997; 71: 3788-3798.
36. Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010; 18: 429-434.
37. Chu RL, Post DE, Khuri FR, Van Meir EG,. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312.
38. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.